PATH-2 trial results published!

Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).

Lowe DM. et al, (2027), Lancet Microbe

Multi-objective optimisation of 3D-printed multilayer TPMS osteochondral scaffolds for enhanced mechanical and biological performance

Xu Y. et al, (2026), Virtual and Physical Prototyping, 21

Subharmonics are not an infallible safety metric for cavitation dynamics.

Wu Q. et al, (2026), Int J Hyperthermia, 43

TTC7A deficiency: A retrospective international study on treatment and outcomes from the Inborn Errors Working Party of EBMT.

Prunotto G. et al, (2026), J Hum Immun, 2

Weaning in INfant hip DYsplasia (WINDY) study: weaning of brace treatment versus immediate cessation for developmental dysplasia of the hip : study protocol for a randomized multicentre feasibility study.

Craven J. et al, (2026), Bone Jt Open, 7, 900 - 906

Systemic Biomarkers of Treatment Response to Methotrexate in People with Painful Knee Osteoarthritis: a Biological Substudy of the PROMOTE Randomised Controlled Clinical Trial.

Liang J. et al, (2026), Osteoarthritis Cartilage

Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomized, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial

Coates L., (2026), Annals of the Rheumatic Diseases

AlphaEarth Satellite Embeddings for Modelling Climate Sensitive Diseases Towards Global Health Resilience

Nazir U. and Sara K., (2026)

Immunometabolic mechanisms across psoriatic disease: Linking psoriasis to psoriatic arthritis

Coates L. et al, (2026), Clinical Rheumatology

Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF : post hoc analysis of SELECT-PsA 2

Coates L., (2026), RMD Open

Psoriatic Arthritis and Obesity: A Review of Clinical Burden and Considerations for Comprehensive Care

Coates L., (2026), RMD Open

TaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a study protocol

Brewer G. et al, (2026), Trials, 27

Hospital costs attributable to further fracture, reoperation, and death during the first year following hip fracture in England : a nationwide cohort study.

Baji P. et al, (2026), Bone Joint J, 108-B, 952 - 960

Assessing the Importance of Variation in Diagnostic Coding Among the Three Countries in the UK Biobank.

Clifton L. et al, (2026), Learn Health Syst, 10

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

Coates LC. et al, (2026), RMD Open, 20, e043855 - e043855

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST

Coates LC. et al, (2026), Rheumatology

Optimal management of pyogenic flexor tenosynovitis of the hand: a cohort study

Hennessy M. et al, (2026), Journal of Hand and Microsurgery, 18

Targeting SYK to alleviate MDSC-driven immunosuppression and augment anti-PD1 efficacy.

Zeng Z. et al, (2026), Sci China Life Sci

Metabolic control of RNA splicing by polyamines.

Hofer SJ. et al, (2026), Trends Biochem Sci

Threat assessment shapes neutrophil cell fate upon inflammasome activation.

Yow SJ. et al, (2026), Sci Adv, 12

Search results

Showing results for